| 描述信息 |
The results of phase II prospective randomized clinical trial (TORCH, NCT04518280) showed over half of microsatellite stable (MSS) locally advanced rectal cancer (LARC) patients could achieve a CR following neoadjuvant short-course radiotherapy combined with immunotherapy. Here, we collected tumor samples from the TORCH trial and performed single-cell sequencing and spatial transcriptomics, with the aim to explore cell dynamics and their association with therapeutic efficacy. In the study, we obtained the single-cell transcriptome data for 217,310 high-quality cells. Subsequent analyses of cell-cell communication, co-occurrence patterns, and spatial transcriptomics systematically mapped the distinct tumor microenvironment of well and poor responders, highlighting unique multicellular interactions and coordination patterns specific to each group. Overall, our study reveals that neoadjuvant radiotherapy combined with immunotherapy synergize to boost immune response in MSS LARC patients and provides valuable insights for identifying targets to improve treatment outcomes. |
